IP Library Granted Patent US 7,368,576
Granted Patent B2
US 7,368,576 · App. 11/481,349 · Granted May 6, 2008

Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents

Assignee: Probiodrug AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,368,576
App. No.
11/481,349
Granted
May 6, 2008
Kind
B2
Abstract

The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for treating conditions mediated by DPIV or DPIV-like enzymes, such as cancer and tumors. In a more preferred embodiment, the compounds of the present invention are useful for the treatment of metastasis and tumor colonization.

Claims (10)

1. A method for treating breast cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of at least one inhibitor of fibroblast activation protein alpha (FAPα), wherein said inhibitor is an amino acid linked to a thiazolidine or a pyrrolidine group by a peptide bond.

2. The method according to claim 1 , wherein treating comprises treating tumor cell metastasis.

3. The method according to claim 1 , wherein treating comprises treating tumor colonization.

4. The method according to claim 1 wherein the at least one inhibitor is selected from the group consisting of L-threo-isoleucyl pyrrolidine, L-allo-isoleucyl thiazolidine, L-allo-isoleucyl pyrrolydine, L-glutaminyl thiazolidine, L-glutaminyl pyrrolidine, L-glutamic acid thiazolidine, L-glutamic acid pyrrolidine and salts thereof.

5. A method according to claim 1 wherein the amino acid is selected from the group consisting of leucine, valine, glutamine, glutamic acid, proline, isoleucine, asparagines and asparatic acid.

6. A method for treating breast cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition which comprises at least one inhibitor of dipeptidyl peptidase IV (DPIV) or fibroblast activation protein alpha (FAPα), wherein said inhibitor is an amino acid linked to a thiazolidine or a pyrrolidine group by a peptide bond.

7. The method according to claim 6 , wherein treating comprises treating tumor cell metastasis.

8. The method according to claim 6 , wherein treating comprises treating tumor colonization.

9. The method according to claim 6 wherein the at least one inhibitor is selected from the group consisting of L-threo-isoleucyl pyrrolidine, L-allo-isoleucyl thiazolidine, L-allo-isoleucyl pyrrolydine, L-glutaminyl thiazolidine, L-glutaminyl pyrrolidine, L-glutamic acid thiazolidine, L-glutamic acid pyrrolidine and salts thereof.

10. A method according to claim 6 wherein the amino acid is selected from the group consisting of leucine, valine, glutamine, glutamic acid, proline, isoleucine, asparagines and asparatic acid.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2006
From: DEMUTH, HANS-ULRICH; HOFFMANN, TORSTEN; VON HORSTEN, STEPHEN
To: PROBIODRUG AG
Reel/Frame 018255/0406 →
Priority Claims (3)
EP 01114796 · Jun 27, 2001 · regional
DE 101 50 203 · Oct 12, 2001 · national
DE 101 54 689 · Nov 9, 2001 · national
Continuity (5)
Division 1109399100 · Mar 30, 2005
Continuation 1017280900 · Jun 13, 2002
Provisional Application 6030115800 · Jun 27, 2001
Provisional Application 6036090900 · Feb 28, 2002
Related Publication 20060293248A1 · Dec 28, 2006